Day: November 9, 2024

ALK (ALKB:DC / OMX: ALK B) today announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, Inc. (“ARS Pharma”, NASDAQ: SPRY). The agreement grants ALK exclusive global rights to the neffy® adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Zealand, Japan and China. The deal delivers on key elements in ALK’s new strategy Allergy+ and supports ALK’s long-term financial ambitions. Needle-free, nasal delivery of adrenaline has the potential to become an important treatment option in anaphylaxis ALK also gains rights to future indications, including acute urticaria flares (in development) ALK to pay USD 145 million in upfront and additional future milestones and sales royalties neffy® is the first and only approved needle-free emergency treatment for patients experiencing...

Novel H2CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on Tumor Cells in Preclinical Studies Initial Low-Dose Cohort of FT825 / ONO-8250 as Monotherapy Shows Favorable Safety Profile in Phase 1 Solid Tumor Study Peripheral Blood from First Three Patients Demonstrates CAR T-cell Expansion with Maintenance of Activated State at Day 8 Following Treatment SAN DIEGO, Nov. 09, 2024 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today presented initial clinical and new preclinical data for FT825 / ONO-8250, a multiplexed-engineered, chimeric antigen receptor (CAR) T-cell product candidate...

Data presented in an oral session at the Society for Immunotherapy of Cancer 39th Annual Meeting, where it was selected as a top 100 abstract BURLINGAME, Calif., Nov. 09, 2024 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new data highlighting the potential of ciforadenant, the Company’s adenosine A2A receptor antagonist, to overcome resistance to anti-PD1 immunotherapy in the treatment of metastatic castration resistant prostate cancer (mCRPC). The data were presented today in an oral session at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting by Aram Lyu, Ph.D., a postdoctoral fellow at Fred Hutch Cancer Center, University of California, San Francisco and Parker Scholar at the Parker Institute for Cancer Immunotherapy. Dr. Lyu’s abstract,...

Oral presentation highlighting IGNYTE primary analysis data shows anti-tumor activity across all subgroups with injected and non-injected lesions responding with similar frequency, depth, duration, and kinetics Initial biomarker data shows increase in tumor CD8+ T cell and PD-L1 expression after dosing along with an increase in gene signatures associated with CD8+ T cells and inflammatory cytokines, highlighting the potential of RP1 plus nivolumab to generate a potent anti-tumor immune response WOBURN, Mass., Nov. 09, 2024 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the primary analysis data from the IGNYTE clinical trial, including initial biomarker analyses, was presented as a late-breaking abstract...

Phase 1/2 data show improvements across all domains and confirm that Phase 3 Aspire study is amply powered to establish efficacy of GTX-102 Phase 3 program on track to begin enrollment by end-of-year NOVATO, Calif., Nov. 09, 2024 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced Phase 1/2 data in support of the Phase 3 Aspire study for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, that will be presented at the 2024 Foundation for Angelman Syndrome Therapeutics (FAST) Global Science Summit in Orlando, Florida. “Cognition is the building block for the development and ascertainment of many new skills across a range of the domains we have evaluated in the Phase 1/2 study. The data presented at FAST reinforce that the Aspire Phase 3 primary endpoint of cognition, as measured...

OMAHA, Neb., Nov. 09, 2024 (GLOBE NEWSWIRE) — Exodus Movement, Inc. (OTCQX: EXOD), (the “Company” or “Exodus”) the leading self-custodial cryptocurrency software platform, will release financial results for the third quarter ended September 30, 2024 following the close of the U.S. markets on November 12, 2024. Exodus will host a webcast to discuss its results at 5:00 p.m. Eastern Time the same day. To access the webcast, please use this link. It will also be carried on the Company’s website www.exodus.com. Supplementary materials will also be made available prior to the webcast on the “Investor Relations” portion of the Company website. Contact Exodus Customer Supportsupport@exodus.com Contact Exodus Investor Relationsinvestors@exodus.com About Exodus Exodus is a financial technology leader empowering individuals and businesses...

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Nov. 08, 2024 (GLOBE NEWSWIRE) — VERSES AI Inc. (CBOE: VERS) (OTCQX:VRSSF) (“VERSES” or the “Company”) is pleased to announce that it closed its previously announced non-brokered private placement of 3,600,000 special warrants of the Company (the “Special Warrants”) at a price of $0.50 (the “Offering Price”) per Special Warrant for aggregate gross proceeds of $1.8 million (the “Special Warrant Offering”). The Company’s decision to increase the size of the Special Warrant Offering from $1.6 million to $1.8 million was accepted by Cboe Canada (the “Exchange”) prior to closing. Each Special Warrant is exercisable, at no additional costs, for one unit of the Company (each, an “Equity Unit”). Each Equity...

VANCOUVER, British Columbia, Nov. 08, 2024 (GLOBE NEWSWIRE) — The Keg Royalties Income Fund (the “Fund”) (TSX: KEG.UN) today announced that its November 2024 distribution of $0.0946 per unit has been declared and is payable to unitholders of record as at November 21, 2024. The November 2024 distribution will be paid on November 29, 2024. The Fund is a limited purpose, open-ended trust established under the laws of the Province of Ontario that, through The Keg Rights Limited Partnership, a subsidiary of the Fund, owns certain trademarks and other related intellectual property used by Keg Restaurants Ltd. (“KRL”). In exchange for use of those trademarks, KRL pays the Fund a royalty of 4% of gross sales of Keg restaurants included in the royalty pool. With approximately 10,000 employees, over 100 restaurants and annual system sales...

NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) today announced that AppLovin Corporation (Nasdaq: APP), will become a component of the Nasdaq-100 Index® (Nasdaq: NDX®) and the Nasdaq-100 Equal Weighted™ Index (Nasdaq: NDXE™) prior to market open on Monday, November 18, 2024. AppLovin Corporation will replace Dollar Tree, Inc. (Nasdaq: DLTR) in the Nasdaq-100 Index® and the Nasdaq-100 Equal Weighted™ Index. Dollar Tree, Inc. will also be removed from the Nasdaq-100 Ex-Tech Sector™ Index (Nasdaq: NDXX™), the Nasdaq-100 ESG™ Index (Nasdaq: NDXESG™), the Nasdaq-100 Sustainable ESG Select™ Index (Nasdaq: NDXSES™) , the Nasdaq-100 ex Top 30™ Index (Nasdaq: NDX70™), and the Nasdaq-100 ex Top 30 UCITS™ Index (Nasdaq: NDX70U™) on...